1

Research Study process

Student Name

University

Course

Name of Instructor

Date
 2

Research Study process

Problem gap There is promising yet inconsistent evidence that microbiome-

targeted adjuncts (especially probiotics/ “psychobiotics”) can

reduce depressive symptoms, but guidance is unclear for adults

with TRD, particularly regarding who benefits, optimal

protocols, and psychological outcomes (e.g., anhedonia,

rumination, affective bias). Clinicians therefore lack evidence-

based adjunct parameters to enhance standard psychiatric care for

TRD (Rahmannia et al., 2024).

Purpose of the Study Purpose: To test whether an 8-week adjunct probiotic improves

(including method and depressive symptoms and key psychological processes

design) (anhedonia, rumination, negative affective bias) in adults with

TRD receiving stable antidepressant treatment.

Method/Design: A randomized, double-blind, placebo-controlled

trial (parallel groups) conducted in routine outpatient psychiatric

settings. The psychology perspective is crucial and outcomes

prioritize validated psychological measures and symptom change

trajectories (Rahmannia et al., 2024).

1-2 Research Questions/ RQ1 (primary): Among adults with TRD on stable

Hypotheses (null and pharmacotherapy, does adjunct probiotic vs placebo lead to

alternative) greater reduction in depressive symptoms over 8 weeks?

H0: There is no difference in depressive-symptom trajectories

between groups.
 3

H1: Probiotic produces greater depressive-symptom reduction

than placebo.

RQ2 (mechanism, psychology-focused): Does change in

rumination and/or anhedonia mediate the effect of probiotic on

depressive symptoms?

H0: Changes in rumination/anhedonia do not mediate treatment

effects.

H1: Reductions in rumination and/or increases in hedonic

capacity partly mediate symptom improvement.

Population, Sampling and Population and frame: Adults (18–65) meeting DSM-5 criteria

recruitment - Sampling for MDD with TRD (≥2 adequate antidepressant trials failed),

frame and sampling currently in outpatient psychiatric care.

method (including Inclusion criteria: stable antidepressant dose ≥4 weeks; baseline

recruitment strategy) and moderate severity. Exclusion: current psychosis, bipolar disorder,

Sample size (justified by active SUD requiring detox, urgent suicide risk, recent probiotic

scholarly sources and use that cannot be washed out.

power analysis for Sampling method: Consecutive, eligibility-screened volunteers

quantitative studies, from partner clinics plus targeted community/online outreach;

discussing the role of randomization 1:1 to probiotic or placebo.

saturation for qualitative Recruitment strategy: clinician referral at medication-

studies) management visits, flyers/portal messages, and IRB-approved

digital ads directing to a brief prescreener.

Sample size (quantitative): A practical target of N=128 (64/arm)

achieves ≈80% power (α=.05, two-tailed) to detect a moderate

effect (d≈0.5) on continuous depressive symptoms using mixed-

effects modeling with repeated measures and expected retention

≥85%. This balances feasibility and sensitivity typical of adjunct

TRD trials. (If a small qualitative exit-interview substudy is

added for patient experience/usability, plan n≈12–20 interviews,

with analysis continuing until thematic saturation is reached.)

Data collection strategy Setting: One to two outpatient psychiatry clinics (and/or a

and Research setting university-affiliated mood clinic) to ensure realistic recruitment

(location for study and oversight.

procedures and data Timeline and visits: Baseline (Week 0), mid-treatment (Week 4),

collection) post-treatment (Week 8), and follow-up (Week 12, brief). Mode:

In-person for baseline and Week 8; Week 4 and Week 12 can be

telehealth to reduce burden.

Adherence and safety: Pill counts, brief AE checklist, and

automated reminders. Psychological scales are completed

electronically before visits to streamline sessions (Schaub et al.,

2022).

Operationalization and Independent variable: Adjunct probiotic capsule (well-

instruments (including characterized multi-strain used in prior MDD work) vs placebo,

specific measurement daily for 8 weeks; both groups remain on stable antidepressant

instruments or interview regimens.

protocols for all Primary outcome (depression): IDS-SR or MADRS (clinician-

constructs/variables or rated) with PHQ-9 as a pragmatic secondary.

phenomena of interest) Psychological mechanisms: Rumination (Ruminative Responses

Scale-10), Anhedonia (Snaith–Hamilton Pleasure Scale,

SHAPS), and negative affective bias (brief computerized affect-

bias task or a validated short form feasible in clinic).

Function/quality: WSAS or SDS. Anxiety (secondary): GAD-7

or HAMA.

Safety/tolerability: brief GI symptom checklist; AEs captured at

each contact. (Optional minimal biology to contextualize

psychology: high-level CRP or a short mood-related cytokine

panel if budget permits; this is not required.)

Data analysis (identify the For RQ1 (primary efficacy): Use linear mixed-effects models

specific process or (time nested within participants) with fixed effects for Group

analysis you will use to (probiotic vs placebo), Time (0, 4, 8 weeks), and Group×Time,

answer each RQ) adjusting for baseline severity; report estimated marginal means,

effect sizes, and 95% CIs; conduct intention-to-treat with

multiple imputation for intermittent missingness and a per-

protocol sensitivity check.

For RQ2 (mediation-psychology focus): Test longitudinal

mediation with changes in rumination/anhedonia from baseline

to Week 4 predicting Week-8 depression, using path models (e.g.,

SEM or PROCESS-style models with bias-corrected

bootstrapping). Exploratory: moderation by baseline anxiety or

anhedonia severity; clinically meaningful response/remission

rates (e.g., ≥50% reduction; MADRS ≤10).

Part 2

Influence of Examples and Assignment Requirements

The development of the revised research questions and hypotheses was guided by

structure and clarity emphasized in the examples and rubric provided in the assignments. The

examples demonstrated the importance of ensuring each component flows logically. This

included measurable and testable outcomes to support the approach. The approach refined the

research questions to make them more specific, feasible, and measurable. They were refined to

focus on psychological constructs rather than biological markers (Johnson & Steenbergen, 2025).

An example was instead of emphasizing gut-microbiome mechanisms, the new research

questions target psychological mediators such as rumination and anhedonia. This aligns with

evidence-based psychological theory in cognitive and affective processes in depression.

The assignment required the inclusion of clear null and alternative hypotheses. It required

a shift toward a quantitative experimental design (randomized controlled trial). The research

questions were formulated to directly align with statistical testing (mixed-effects modeling for

primary outcomes and mediation analysis for mechanisms). This included the need for

operational clarity for psychological scales like the Ruminative Responses Scale and Snaith-

Hamilton Pleasure Scale to connect the hypotheses to measurable constructs (Johnson &

Steenbergen, 2025). This resulted in a design that remains scientifically rigorous and suitable for

real-world psychiatric setting.

Alignment of Problem/Purpose/RQs
 7

The problem, purpose, and research questions are highly aligned both conceptually and

methodologically. The problem identifies a clear gap that is the lack of consistent, clinically

applicable evidence about adjunct probiotic use in adults with treatment-resistant depression.

This gap specifically pertains to psychological mechanisms of change. The purpose statement

directly responds to this gap by proposing a controlled trial to evaluate the psychological effects

(symptom reduction, rumination, and anhedonia) of an adjunct probiotic intervention. The

research questions and hypotheses flow naturally from this purpose (Nikolova et al., 2023). They

quantify the intended investigation through well-defined psychological variables. The alignment

is significant for internal coherence. Each of the included components builds logically on the last

and reduces the risk of conceptual drift. It also promotes consistency of the methodology

throughout the study. The quantitative randomized control trial design suits both the causal

nature of the primary question and process-oriented secondary question.

Ethical Consideration of Research Processes

The first ethical consideration is informed consent from participants. Participants with

TRD are a potentially vulnerable population because of depressive symptoms and impaired

motivation. These individuals need to be provided with appropriate resources to help them

understand study procedures, randomization, potential risks, and their right to withdraw at any

time without penalty is crucial. The process should involve using plain and nontechnical

language with opportunities for clarification. The second ethical consideration is the balance

between risk and benefit. The probiotic intervention carries minimal physical risk, but

participants may experience emotional distress when completing self-report measures about

mood or discussing sensitive topics (Khaled et al., 2025). This requires inclusion of procedures

to monitor depressive severity and suicidality at each visit, with clear referral pathways for
 8

urgent care if risk escalates. The third ethical consideration is confidentiality of patient data. The

process will involve securing psychological data, electronic surveys, and clinical notes. It will

also involve separating identifiable information from coded study IDs for improved data

security. Equitable recruitment is crucial to meet ethical standards. The processes will ensure

inclusivity across gender, ethnicity, and socioeconomic status to reflect the diversity of adults

with TRD. Compensation will also be fair but not coercive for participants (Khaled et al., 2025).
 9

References

Johnson, K. V., & Steenbergen, L. (2025). Probiotics reduce negative mood over time: the value

of daily self-reports in detecting effects. Npj Mental Health Research, 4(1).

[Link]

Khaled, K., Tsofliou, F., & Hundley, V. (2025). Ethical issues and challenges regarding the use

of mental health questionnaires in public health nutrition research. Nutrients, 17(4), 715.

[Link]

Nikolova, V. L., Cleare, A. J., Young, A. H., & Stone, J. M. (2023). Acceptability, tolerability,

and estimates of putative treatment effects of probiotics as adjunctive treatment in

patients with depression. JAMA Psychiatry, 80(8), 842.

[Link]

Rahmannia, M., Poudineh, M., Mirzaei, R., Aalipour, M. A., Bonjar, A. H. S., Goudarzi, M.,

Kheradmand, A., Aslani, H. R., Sadeghian, M., Nasiri, M. J., & Sechi, L. A. (2024).

Strain-specific effects of probiotics on depression and anxiety: a meta-analysis. Gut

Pathogens, 16(1). [Link]

Schaub, A., Schneider, E., Vazquez-Castellanos, J. F., Schweinfurth, N., Kettelhack, C., Doll, J.

P. K., Yamanbaeva, G., Mählmann, L., Brand, S., Beglinger, C., Borgwardt, S., Raes, J.,

Schmidt, A., & Lang, U. E. (2022). Clinical, gut microbial and neural effects of a

probiotic add-on therapy in depressed patients: a randomized controlled trial.

Translational Psychiatry, 12(1). [Link]